Evoke Pharma INC Form 4 insider transactions

Nantahala Capital Management, a 10% owner of Evoke Pharma Inc., disposed of all its common stock and warrants following the company's merger with QOL-EOS Merger Sub, Inc.

Evoke Pharma director Greg Pyszczymuka's stock options were canceled and converted to cash following the company's merger with QOL Medical, LLC.

Evoke Pharma director Benjamin C. Smeal cashed out all his stock options following the company's merger with QOL Medical, LLC, effective December 17, 2025.

Evoke Pharma's Chief Medical Officer reported the disposition of common stock and cash-out of stock options following the company's acquisition by QOL Medical.

Evoke Pharma Director Cam L. Garner reports the disposition of common stock and cash conversion of stock options following the company's acquisition by QOL Medical, LLC.

Evoke Pharma Director Malcolm R. Hill reported the sale of common stock and cancellation of stock options following the company's acquisition by QOL Medical, LLC for $11.00 per share.

Evoke Pharma Inc. has been acquired by QOL Medical, LLC, with Chief Financial Officer Mark Kowieski disposing of his common stock and converting options into cash.

Evoke Pharma Director Kenneth J. Widder converted his stock options into cash following the company's merger with QOL Medical, LLC.

Evoke Pharma Director Todd C. Brady reported the disposition of common stock and the cash conversion of stock options following the company's acquisition by QOL Medical, LLC.

Evoke Pharma Director Vickie S. Reed converted all outstanding stock options into cash following the company's merger with QOL Medical, LLC.

Evoke Pharma Inc.'s CEO, Matthew J. D'Onofrio, reported the disposition of common stock and stock options following the company's acquisition by QOL Medical, LLC.

Evoke Pharma Director Roger M. Klein reported the sale of 9,000 shares of common stock on November 6, 2025, pursuant to a Rule 10b5-1 trading plan.

Director Todd C. Brady acquired stock options in Evoke Pharma, Inc. on May 21, 2025.

Director Malcolm R. Hill reports the acquisition of stock options in Evoke Pharma, Inc.

Director Cam L. Garner reports acquisition of stock options in Evoke Pharma, Inc.

Director Vickie S. Reed acquired stock options for 1,250 shares of Evoke Pharma Inc. common stock on May 21, 2025.

Director Kenneth J. Widder reports the acquisition of stock options in Evoke Pharma, Inc.

Director Benjamin C. Smeal of Evoke Pharma acquired stock options exercisable for 1,125 shares of common stock on May 21, 2025.

Director Greg Pyszczymuka of Evoke Pharma, Inc. reports the acquisition of stock options exercisable for 1,155 shares of common stock.

Evoke Pharma's CEO, Matthew J. D'Onofrio, reports acquiring 1,000 shares of common stock at $2.7972 per share and disposing of 9,820 shares on March 21, 2025.

Mark Kowieski, CFO of Evoke Pharma, reports the acquisition and disposal of company stock on March 20, 2025.

Matthew J. D'Onofrio, CEO of Evoke Pharma, reports acquisition of shares through the company's Employee Stock Purchase Plan.

Director Greg Pyszczymuka of Evoke Pharma Inc. reports the acquisition of stock options.

Nantahala Capital Management, along with related individuals, reported the sale of 41 shares of Evoke Pharma Inc. at a price of $4.3871 per share.

Evoke Pharma's CEO, Matthew J. D'Onofrio, was granted 70,000 stock options on January 28, 2025, according to a Form 4 filing with the SEC.

Director Kenneth J. Widder reports the acquisition of stock options in Evoke Pharma, Inc.

Director Vickie S. Reed reports the acquisition of stock options in Evoke Pharma, Inc.

Malcolm R. Hill, a director of Evoke Pharma Inc, reports the acquisition of stock options.

Director Todd C. Brady of Evoke Pharma Inc. reports acquisition of stock options exercisable for 5,833 shares of common stock.

Director Cam L. Garner of Evoke Pharma Inc. reports the acquisition of stock options on January 28, 2025.